Evidence map›Paper›PMID 33053333›Full record

ArticleImmunity2020

Second-Strand Synthesis-Based Massively Parallel scRNA-Seq Reveals Cellular States and Molecular Features of Human Inflammatory Skin Pathologies.

Travis K Hughes, Marc H Wadsworth, Todd M Gierahn, Tran Do, David Weiss, Priscila R Andrade, Feiyang Ma, Bruno J de Andrade Silva, Shuai Shao, Lam C Tsoi and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Immunity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 182 papers.

0numbers the graph read from it
0cells of the map it votes in
182citing papers in PubMed
13.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

182 citing papers in PubMed, 272 citations in OpenAlex.

  1. Review
  2. Mapping Embryonic Mouse Lung Development Using Enhanced Spatial Transcriptomics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Hidden immune memory niches in inflammatory skin diseases.bioRxiv : the preprint server for biology · 2026
    Article
  15. Article
  16. Article
  17. When Checkpoint Inhibitors Break Barriers: Mechanisms and Challenges of irAEs of the Skin, Gastrointestinal Tract, and Lung.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Review
  18. Article
  19. Article
  20. Article

122 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Travis K HughesInstitute for Medical Engineering & Science (IMES), MIT, Cambridge, Massachusetts, USA; Department of Immunology, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA; Department of Chemistry, MIT, Cambridge, Massachusetts, USA.
Marc H WadsworthInstitute for Medical Engineering & Science (IMES), MIT, Cambridge, Massachusetts, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA; Department of Chemistry, MIT, Cambridge, Massachusetts, USA.
Todd M GierahnKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA; Department of Chemical Engineering, MIT, Cambridge, MA, USA.
Tran DoDivision of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Department of Microbiology, Immunology and Molecular Biology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
David WeissDivision of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Department of Microbiology, Immunology and Molecular Biology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Priscila R AndradeDivision of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Department of Microbiology, Immunology and Molecular Biology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Feiyang MaDivision of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Department of Microbiology, Immunology and Molecular Biology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Bruno J de Andrade SilvaDivision of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Department of Microbiology, Immunology and Molecular Biology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Shuai ShaoDepartment of Dermatology, University of Michigan, Ann Arbor, MI, USA.
Lam C TsoiDepartment of Dermatology, University of Michigan, Ann Arbor, MI, USA.
Jose Ordovas-MontanesBroad Institute of MIT and Harvard, Cambridge, MA, USA; Division of Gastroenterology, Boston Children's Hospital, Boston, MA, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, USA; Harvard Stem Cell Institute, Cambridge, MA, USA.
Johann E GudjonssonDepartment of Dermatology, University of Michigan, Ann Arbor, MI, USA.
Robert L ModlinDivision of Gastroenterology, Boston Children's Hospital, Boston, MA, USA.
J Christopher LoveBroad Institute of MIT and Harvard, Cambridge, MA, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA; Department of Chemical Engineering, MIT, Cambridge, MA, USA. Electronic address: clove@mit.edu.
Alex K ShalekInstitute for Medical Engineering & Science (IMES), MIT, Cambridge, Massachusetts, USA; Department of Immunology, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA; Harvard Stem Cell Institute, Cambridge, MA, USA. Electronic address: shalek@mit.edu.
University of California, Los Angeles · USHarvard University · USKoch Institute for Integrative Cancer Research At MITUniversity of Michigan–Ann Arbor · USBoston Children's Hospital · US

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Paula T Hammond · 1985 to 2026
$93.9M
Role of Negative Costimulation in Regulation of AutoimmunityP01AI039671 · NIAID · YALE UNIVERSITY · PI David A. Hafler · 1996 to 2026
$51.7M
Systems investigation of vaccine responses in B cell depleted autoimmune patientsU19AI089992 · NIAID · YALE UNIVERSITY · PI David A. Hafler, RUTH R MONTGOMERY · 2010 to 2026
$50.4M
TCR recognition of MHC class II peptide compexes in multiple sclerosisP01AI045757 · NIAID · DANA-FARBER CANCER INSTITUTE · PI KUCHROO, VIJAY K., LOVE, JOHN CHRISTOPHER · 1999 to 2017
$22.8M
Molecular Analysis of the Host Immune Response in LeprosyR01AI022553 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ROBERT L MODLIN · 1989 to 2026
$15.7M
The Cellular Geography of Therapeutic Resistance in CancerU2CCA233195 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2018 to 2023
$13.7M
TCR GAMMA/DELTA LYMPHOCYTES IN HUMAN SKIN LESIONSR01AR040312 · NIAMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MODLIN, ROBERT L · 1990 to 2025
$10.4M
University of Michigan Skin Biology and Diseases Resource-based CenterP30AR075043 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Johann Eli Gudjonsson · 2019 to 2026
$6.6M
Role of the sex biased transcription factor VGLL3 in promoting autoimmune responses in SLER01AI130025 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Johann Eli Gudjonsson · 2017 to 2026
$3.9M
The skin microbiome in acneR01AR074302 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GALLO, RICHARD L, MODLIN, ROBERT L · 2018 to 2022
$2.6M
IL-26 in host defense against infection by intracellular bacteria in skinR01AR073252 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MODLIN, ROBERT L · 2019 to 2023
$2.1M
Role of the Psoriasis Associated IL23R Risk Variants on Th17 Biology and FunctionK08AR060802 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GUDJONSSON, JOHANN ELI · 2011 to 2015
$636k
Howard Hughes Medical InstituteNCI NIH HHS P30 CA014051NCI NIH HHS U2C CA233195NIAID NIH HHS F30 AI143160NIAID NIH HHS N01 AI030025NIAID NIH HHS P01 AI039671NIAID NIH HHS P01 AI045757NIAID NIH HHS R01 AI022553NIAID NIH HHS R01 AI130025NIAID NIH HHS U19 AI089992NIAMS NIH HHS K08 AR060802NIAMS NIH HHS P30 AR075043NIAMS NIH HHS R01 AR040312NIAMS NIH HHS R01 AR073252NIAMS NIH HHS R01 AR074302
6 · The paper itself

Abstract

High-throughput single-cell RNA-sequencing (scRNA-seq) methodologies enable characterization of complex biological samples by increasing the number of cells that can be profiled contemporaneously. Nevertheless, these approaches recover less information per cell than low-throughput strategies. To accurately report the expression of key phenotypic features of cells, scRNA-seq platforms are needed that are both high fidelity and high throughput. To address this need, we created Seq-Well S

Indexed as

AnimalsCell LineDNA, ComplementaryHEK293 CellsHigh-Throughput Nucleotide SequencingHumansInflammationMiceNIH 3T3 CellsRNA, Small CytoplasmicSequence Analysis, RNASingle-Cell AnalysisSkinTranscription, GeneticTranscriptomeDNA, ComplementaryRNA, Small Cytoplasmicacnealopecia areatagranuloma annulareleprosypsoriasisscRNA-seqSeq-Wellsingle-cell RNA sequencingskin inflammation

Identifiers

PMID33053333
PMCPMC7562821
OpenAlexW3093368337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.